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REPORT
Joint Analysis of Psychiatric Disorders Increases
Accuracy of Risk Prediction for Schizophrenia,
Bipolar Disorder, and Major Depressive Disorder
Robert Maier,1 Gerhard Moser,1 Guo-Bo Chen,1 Stephan Ripke,2 Cross-Disorder Working Group of the
Psychiatric Genomics Consortium, William Coryell,3 James B. Potash,3 William A. Scheftner,4
Jianxin Shi,5 Myrna M. Weissman,6 Christina M. Hultman,7 Mikael Lande´n,7,8 Douglas F. Levinson,9
Kenneth S. Kendler,10 Jordan W. Smoller,11 Naomi R. Wray,1 and S. Hong Lee1,*
Genetic risk prediction has several potential applications in medical research and clinical practice and could be used, for example,
to stratify a heterogeneous population of patients by their predicted genetic risk. However, for polygenic traits, such as psychiatric
disorders, the accuracy of risk prediction is low. Here we use a multivariate linear mixed model and apply multi-trait genomic best linear
unbiased prediction for genetic risk prediction. This method exploits correlations between disorders and simultaneously evaluates indi-
vidual risk for each disorder. We show that the multivariate approach significantly increases the prediction accuracy for schizophrenia,
bipolar disorder, andmajor depressive disorder in the discovery as well as in independent validation datasets. By grouping SNPs based on
genome annotation and fitting multiple random effects, we show that the prediction accuracy could be further improved. The gain in
prediction accuracy of the multivariate approach is equivalent to an increase in sample size of 34% for schizophrenia, 68% for bipolar
disorder, and 76% for major depressive disorders using single trait models. Because our approach can be readily applied to any number
of GWAS datasets of correlated traits, it is a flexible and powerful tool to maximize prediction accuracy. With current sample size, risk
predictors are not useful in a clinical setting but already are a valuable research tool, for example in experimental designs comparing
cases with high and low polygenic risk.
Genome-wide association studies (GWASs) have been
highly successful in identifying variants associated with a
wide range of complex human diseases.1,2 However, most
common diseases are highly polygenic and each variant
explains only a tiny proportion of the genetic variation.
Even when associated SNPs are considered jointly in
polygenic approaches such as polygenic risk scores3 or
genomic best linear unbiased prediction (GBLUP),4,5 the
accuracy of risk prediction is low. The use of more
advanced methods4–8 improved prediction accuracy for
traits where a small number of relatively strong associa-
tions have been identified, such as type 1 diabetes, anky-
losing spondylitis, and rheumatoid arthritis, but not for
other traits characterized by small effect size variants,
including psychiatric disorders.4,5,9
A major factor determining how well a polygenic model
can predict a trait value in an independent sample is the
sample size of the discovery data.10,11 Using more individ-
uals will provide more information and hence increase
the accuracy of the estimated effect size of a specific SNP.
Sample size can also be effectively increased through data-
sets measured for correlated traits. Recently, we estimated
the genetic relationships among five psychiatric disorders
from the Psychiatric Genomics Consortium (PGC) by
using a bivariate linear mixed model demonstrating that
there are significant shared genetic risk factors across the
disorders and that measurement of one trait provides
information on other genetically correlated traits.12 Here
we extend our bivariate approach to a multivariate linear
mixed model and apply multi-trait genomic best linear
unbiased prediction (MTGBLUP)13,14 for genetic risk pre-
diction of disease. MTGBLUP is expected to be more
powerful because it uses correlations between disorders
and jointly evaluates individual risk across disorders. To
date, the information from other correlated traits has
been little exploited in the context of risk prediction
although recently Li et al.9 applied bivariate ridge regres-
sion to two genetically correlated diseases to improve risk
prediction.
An important advantage of the MTGBLUP approach
is that it does not require multiple phenotypes to be
measured on the same individuals and therefore can be
readily applied to any number of existing datasets of
genetically related traits. This is particularly beneficial for
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disease studies that are limited to a single phenotype but
typically aim for large sample sizes. Moreover, it is not
necessary for the datasets to be genotyped with the same
SNP array because SNPs can be imputed to a common set
of SNPs, such as those available from the HapMap or
1000 Genomes reference panels.15,16 Prediction accuracy
can be expected to improve as more data from phenotypes
with shared etiology are utilized.
In this report, we apply the MTGBLUP approach to the
cross-disorder PGC GWAS data and show a significant
increase in risk prediction accuracy in independent co-
horts of schizophrenia, bipolar disorder, and major depres-
sive disorder. MTGBLUP increased the discriminant power
between the top and bottom 10% of individuals ranked
on their risk predictor, implying that this approach might
be useful for stratified medicine in a research setting, to
develop tailored interventions or treatments for individ-
uals having different risks.17–19 We further demonstrate
a relationship between functionally annotated SNPs and
increased prediction accuracy of schizophrenia and bipolar
disorder.
As the main method, we use a multivariate linear mixed
model for the analyses of GWAS data that estimates the
total genetic values of individuals directly by utilizing
genomic relationships based on SNP information. In the
model, a vector of phenotypic observations for each trait
is written as a linear function of fixed effects, random
genetic effects, and residuals. For simplicity, we constrain
the description to a single component for the random
genetic effects, but the model can be readily extended to
multiple components of random genetic effects:
y1 ¼ X1b1 þ Z1g1 þ e1 for trait 1
y2 ¼ X2b2 þ Z2g2 þ e2 for trait 2
«
yn ¼ Xnbn þ Zngn þ en for trait n
where y is a vector of trait phenotypes, b is a vector of fixed
effects, g is a vector of total genetic value for each individ-
ual, and e are residuals. The random effects (g and e) are
assumed to be normally distributed with mean zero. X
and Z are incidencematrices for the effects b and g, respec-
tively. Subscript 1,., n represents trait 1 to trait n. The
variance covariance matrix is defined as
V ¼
2
4 ZAs2g1Z0 þ Is2e1 . ZAsg1nZ0 þ Ise1n« 1 «
ZAsgn1Z
0 þ Isen1 / ZAs2gnZ0 þ Is2en
3
5
where A is the genomic similarity matrix based on SNP in-
formation and I is an identity matrix. The terms s2gi and s
2
ei
denote the genetic and residual variance of trait i, respec-
tively, andsgij andseij thegenetic and residual covariancebe-
tween traits i and j. Multi-trait genomic residual maximum
likelihood (MTGREML) estimates (see Appendix A) are ob-
tained with the average information algorithm.20–22
Next we show that SNP risk predictors can be easily
transformed from individual risk predictors with a simpli-
fied BLUP model that uses individual risk predictors as
the dependent variable and fits a covariance structure
without residual variance (i.e., heritability is 1). Individual
risk predictors are the best linear unbiased predictors
(BLUPs) of total genetic value of individual subjects
contributed by genome-wide SNPs, i.e., g in the previous
section. Analogously, SNP risk predictors are defined as
the BLUPs of SNP effects estimated jointly with a linear
mixed model that intrinsically accounts for linkage
disequilibrium between SNPs. The SNP-BLUP model is
computationally more demanding for a large number of
SNPs. Therefore, it is desirable to estimate genetic values
(GBLUP) for efficiency and to transform them to SNP-
BLUP. The SNP-BLUP can be projected to predict genetic
risk for independent validation sample without the need
to have access to the training individuals. The SNP-BLUP
estimates can be applied to independent datasets as the
SNP weights used to create a risk profile score, for example
using the PLINK-score command. The individual BLUP
model is
2
64
g1
«
gn
3
75 ¼
2
64
s2g1 / sg1n
« 1 «
sgn1 / s
2
gn
3
755A
,
2
64
Z1 / 0
« 1 «
0 / Zn
3
75
0
,V1
2
64
y1 X1b1
«
yn Xnbn
3
75:
(Equation 1)
SNP-BLUP model is
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where Wi is a N 3 M matrix of standardized SNP coeffi-
cients with N being the number of individuals and M the
number of SNPs, 5 is the Kronecker product function,
and the variance covariance matrix for SNP-BLUP mode
is defined as
U ¼
2
4 WIs2u1W0 þ Is2e1 . WIsu1nW0 þ Ise1n« 1 «
WIsun1W
0 þ Isen1 / WIs2gnW0 þ Is2en
3
5:
Replacing y with g (individual BLUP) and setting residual
(co)variances as zero (because individual BLUP is already
adjusted for residuals), the variance covariance matrix
can be simplified as
U ¼
2
4 s2u1 / su1n« 1 «
sun1 / s
2
un
3
55WW0 ¼
2
4 s2u1 / su1n« 1 «
sun1 / s
2
un
3
55A,M:
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Therefore, SNP-BLUP can be written as
2
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(Equation 2)
and this can be rewritten as2
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This agrees with Hayes et al.23 and Yang et al.22 when it
reduces to a univariate model. Equation 2, after replacing
[g1, ., gn]’ with the right-hand side in Equation 1, can
be rewritten as
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(Equation 3)
This agrees with VanRaden24 and Strande´n and Garrick25
derived from a matrix inversion theory when it reduces
to a univariate model.
We extended our approach to genomic partitions
according to gene annotation. An enrichment analysis
based on gene annotation categories has shown that
SNPs located within genes identified as being differentially
expressed in the central nervous system (CNS) explain a
significantly larger proportion of phenotypic variance
than expected by chance for schizophrenia and bipolar
disorder.12,26 It is of interest to determine whether the
gene/functional annotation information can further in-
crease the prediction accuracy. In the annotation analysis,
we grouped SNPs that were located within 550 kb from
the 50 and 30 UTRs of 2,725 genes differentially expressed
in the CNS26,27 together, and 21% of the SNPs belonged
to this category. We then estimated SNP effects from
a two-component model fitting relationship matrices of
SNPs in CNS genes and SNPs localized elsewhere. The
model is
y1 ¼ X1b1 þ Z1g1CNS þ Z1g1nonCNS þ e1 for trait 1
«
yn ¼ Xnbn þ ZngnCNS þ ZngnnonCNS þ en for trait n
where gCNS is a vector of random genetic effects due to
the CNS genes and gnon-CNS is a vector of random genetic
effects resulting from the non-CNS region.
We also tested another gene set that included candidate
genes set for schizophrenia, autism, and intellectual
disability (SAI).3 We matched these candidate genes with
UCSC Genome Browser human genome version 18 (on
which the discovery dataset was built) and retained 4,133
autosomal genes. It is noted that we excluded 479 genes
flanking GWAS SNPs identified in the Swedish sample28
to avoid artifact inflation in prediction accuracy. We anno-
tated SNPs within the SAI genes (28% of the SNPs) and
fitted genomic similarity matrices of the annotated SNPs
and the rest of SNPs in the two-component model.
We had access to the PGC Cross-Disorder data and three
independent validation datasets. The details of the PGC
Cross-Disorder data with additionally available ADHD
samples are described elsewhere.12 The datasets stored in
the PGC central server follow strict guidelines with local
ethics committee approval. Genotype data from each
study cohort were processed through the stringent PGC
pipeline and imputation of autosomal SNPs was carried
out with the HapMap3 reference sample.29 In each imputa-
tion cohort, we retained only SNPs with MAF >0.01 and
imputation R2>0.6. The number of SNPs used in this study
was 745,705. We excluded certain individuals to ensure
that all samples from the five disorders were completely
unrelated in the conventional sense, so that no pair of
individuals had a genome-wide similarity relationship
greater than 0.05. The numbers of case and control
subjects used in this study are shown in Table 1. All pheno-
types were controlled for cohort, sex, and the first 20 prin-
cipal components estimated from genome-wide SNPs.
Adjustments were performed for each trait.
In preliminary analysis, using the multivariate linear
mixed model, we estimated genetic variances and genetic
correlations between the five psychiatric disorders
(Table 1). The estimates agreed with those reported in the
previous study12 (Figure S1) but were slightly less accurate
(larger standard errors) because of the smaller sample
size due to excluding genetically related samples across
all five disorders rather than across only two traits in the
bivariate analyses.
To evaluate the risk prediction performance of
MTGBLUP, we performed within-study cross-validation
of the PCG data, i.e., internal validation. We randomly
split the data for each disease into a training sample
containing ~80% of individuals and a validation sample
containing the remaining ~20%30 and repeated this five
times. For assessing predictive performance in the internal
validation, we calculated the correlation coefficient
between the observed disease status and the predicted
genomic risk score of the validation individuals. We also
regressed observed disease status on risk scores. If the risk
scores are unbiased estimates of genetic risk then the
regression coefficient is expected to be 1, i.e., the covari-
ance between true and estimated risks equals the variance
of estimated risks. Deviations from 1 reflect the degree of
bias of the risk scores. We averaged the correlation and
regression coefficients and estimated empirical standard
errors over five replicates. Using the empirical standard
errors estimates, a t test was performed to assess differences
in prediction accuracy between methods. In the within-
study cross-validation, MTGBLUP outperformed single-
trait genomic best linear unbiased prediction (STGBLUP)
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for all disorders: the gain in prediction accuracy was sig-
nificant for schizophrenia (p < 6.0 3 108) and bipolar
disorder (p < 6.6 3 1011) (Figure S2). The slope from the
regression of disease status on predicted risk score ranged
from 0.88 to 1.14 (Table S1), indicating that the risk scores
are well calibrated.
Results obtained from a within-study validation might
not reflect the true performance when SNP effects esti-
mated from the training data are spuriously associated
with the diseases. To better assess the true prediction po-
tential of MTGBLUP, risk scores derived from the complete
PCG data were validated in independent samples for
schizophrenia, bipolar, and major depressive disorder.
As independent validation sets, we used Swedish schizo-
phrenia28 and bipolar GWAS data31 and the GENRED2
major depressive disorder dataset collected by the same
methods as reported for the GENRED1 dataset.32 SNPs in
the validation data were processed through the same strin-
gent quality control as the discovery data. The Swedish
schizophrenia data were imputed with HapMap3 as refer-
ence. The bipolar disorder data and major depressive disor-
der data were imputed with the 1000Genomes Project data
as reference. Post-imputation quality control was applied
to exclude poorly imputed SNPs from the validation sets.
Finally, we selected SNPs that matched those in the discov-
ery set. The number of SNPs in each validation set is shown
in Table 2. Individuals were removed from the validation
datasets if they had relatedness >0.05 to any one of the
individuals in the discovery set. Table 2 gives the numbers
of case and control subjects in the independent validation
datasets before and after excluding related individuals. In
the discovery set, we obtained SNP solutions by applying
SNP-BLUP (Equation 3) and then projected the SNP
solution to the genotypes of the validation individuals
(Equation 2). For assessing predictive performance in the
independent validation, the correlation and regression
coefficients were used as measures of prediction accuracy
and biasedness, respectively, similar to the internal valida-
tion. A likelihood ratio test (LRT) was used to test for differ-
ences in prediction accuracy between methods comparing
the likelihood of a logistic regression fitting the STGBLUP
to that of a logistic regression fitting the MTGBLUP
and STGBLUP jointly. In the logistic regression models,
case-control status was used as the dependent variable.
In the validation datasets, all phenotypes were controlled
for cohort, sex, and the first 20 principal components
just as in the discovery dataset. This external validation
confirmed the superior performance of MTGBLUP over
STGBLUP (Table 3). From the LRT to test differences in pre-
diction accuracy, the model including MTGBLUP fitted
the data significantly better (p ¼ 2.4 3 1024 for schizo-
phrenia, 6.6 3 1016 for bipolar disorder, and 0.010 for
major depressive disorder) (Table 4). We further tested
the two-components model fitting similarity matrices
based on SNPs annotated in CNS genes and/or SNPs local-
ized elsewhere (MTGBLUP-CNS and STGBLUP-CNS).
Including the CNS component resulted in increased pre-
diction accuracy for schizophrenia and bipolar disorder
(Tables 3 and 4). We also tested a second annotation model
replacing the CNS gene set with a SAI candidate genes set
Table 1. Estimates of SNP Heritability and Genetic Correlations
from Multivariate Analysis of Five Psychiatric Disorders
Disorders Cases Controls
SNP-h2 on the
Liability Scale SE
SCZ 8,826 6,106 0.235 0.011
BIP 5,867 3,328 0.218 0.017
MDD 8,770 6,506 0.286 0.023
ASD 3,086 3,163 0.130 0.024
ADHD 3,997 8,479 0.281 0.022
Genetic
Correlation
SE
BIP/SCZ 5,867/8,826 3,328/6,106 0.590 0.048
MDD/SCZ 8,770/8,826 6,506/6,106 0.365 0.047
MDD/BIP 8,770/5,867 6,506/3,328 0.371 0.060
ASD/SCZ 3,086/8,826 3,163/6,106 0.194 0.071
ASD/BIP 3,086/5,867 3,163/3,328 0.084 0.089
ASD/MDD 3,086/8,770 3,163/6,506 0.054 0.089
ADHD/SCZ 3,997/8,826 8,479/6,106 0.055 0.046
ADHD/BIP 3,997/5,867 8,479/3,328 0.160 0.059
ADHD/MDD 3,997/8,770 8,479/6,506 0.242 0.059
ADHD/ASD 3,997/3,086 8,479/3,163 0.044 0.088
Abbreviations are as follows: SE, standard error; SCZ, schizophrenia; BIP, bipo-
lar disorder; MDD, major depressive disorder; ASD, autism spectrum disorder;
ADHD, attention deficit disorder.
Table 2. Numbers of Cases and Controls in the Independent Validation Data Sets before and after Removing Related Individuals
SCZ (Swedish) BIP (Swedish) MDD (GENRED2)
Cases Controls Cases Controls Cases Controls
All 5,193 6,391 2,208 6,056 831 474
After cut-off QC 4,068 5,471 2,029 5,338 822 466
Number of SNPs 745,631 645,237 673,109
Abbreviations are as follows: SCZ, Swedish schizophrenia GWAS; BIP, Swedish bipolar disorder GWAS; MDD, GENRED2 GWAS.
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(4,133 autosomal genes)3 (MTGBLUP-SAI or STGBLUP-
SAI), but found little improvement due to SAI genes for
three of the disorders (Tables S2 and S3).
When using independent validation samples, the slopes
of the regression of the case-control status on the predictor
were less than 1 (Table 3). The bias was relatively small for
schizophrenia and bipolar disorder but larger for major
depressive disorder. A slope less than 1 implies that the dif-
ference between the true genetic risks in a pair of individ-
uals is less than that of the predicted genetic risk between
them. The bias could be due to low predictive power (e.g.,
MDD) or to heterogeneity between the discovery and vali-
dation sample. In order to assess population differences,
we calculated ancestry principal components from the
POPRES reference sample33,34 and projected them into
the discovery and validation samples and found ancestral
differences between them for each disorder (Figure S3).
We estimated that the SNP correlation21 between the dis-
covery and validation datasets was significantly different
from 1 for schizophrenia and bipolar disorder (Table S4;
the point estimate was lower for major depressive disorder
but the small sample size generated a large standard error
so it was not significantly different from 1). To explore
whether the found heterogeneity reflects real population
differences or is caused by other factors that lead to differ-
ences between the discovery and validation samples such
as batch effects, we looked for evidence of heterogeneity
within PGC discovery samples for schizophrenia, bipolar
disorder, and major depressive disorder (Appendix B). For
each disorder, we divided the discovery sample into four
groups based on the 25%, 50%, and 75% quartile of the
first principal component, which reflects ancestral popula-
tion differences between individuals (Figure S4). Applying
a reaction norm model35,36 (Appendix B), we found signif-
icant heterogeneity attributable to the ancestral popula-
tion differences for schizophrenia and bipolar disorder
(Table S5 and Figure S5). This indicates that for schizo-
phrenia and bipolar disorder, real population heterogene-
ity rather than batch effects contribute to the reduced
SNP correlation between discovery and validation sets.
Previously we reported more heterogeneity between major
depressive disorder cohorts than between schizophrenia
cohorts,12 where cohorts were defined based on sample
collection, genotyping platform, and imputation set.
The lack of evidence of population heterogeneity for the
depression sample here might reflect that population
heterogeneity not detectable given other heterogeneity
within these samples.
After a common epidemiological approach to assess a
continuous risk factor,37 individuals were stratified into
deciles according to the ranked values of the genetic risk
predictors. We estimated the odds ratio of case-control
status by contrasting each decile to the lowest decile
(Figure 1). For all disorders, the odds ratio was highest be-
tween individuals in the highest and lowest decile, ranging
from 1.3 to 5.5. Generally, odd ratios fromMTGBLUP were
larger than those from STGBLUP. For example, for bipolar
disorder MTGBLUP increased the odds ratio by up to
60% compared to STGBLUP (odds ratio of 4.4 and 2.8,
respectively). The discriminant power increased more for
the annotation model with the CNS genes, compared to
the one-component models without annotation (Figure 1).
Table 3. Prediction Accuracy for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder in Independent Validation Data Sets
Correlation Regression Slope
SCZ BIP MDD SCZ BIP MDD
STGBLUP 0.198 0.129 0.045 0.784 0.709 0.304
MTGBLUP 0.222 0.159 0.075 0.815 0.697 0.466
STGBLUP-CNS 0.203 0.132 0.045 0.789 0.719 0.306
MTGBLUP-CNS 0.224 0.162 0.076 0.807 0.690 0.476
Prediction accuracy is given as the correlation coefficient between the observed disease status and the predicted genomic risk score in the validation data. Regres-
sion deviated from one reflects the degree of bias of the risk scores.
Table 4. p Values from the Likelihood Ratio Test Comparing Different Models
x1 x2
SCZ BIP MDD
p Values from LRT
STGBLUP MTGBLUP 2.4 3 1024 6.6 3 1016 1.0 3 102
STGBLUP STGBLUP-CNS 9.1 3 106 4.6 3 103 5.8 3 101
MTGBLUP MTGBLUP-CNS 2.4 3 103 5.3 3 103 3.3 3 101
STGBLUP MTGBLUP-CNS 6.7 3 1026 1.3 3 1017 7.3 3 103
Likelihood ratio LR ¼ 2 [logL(x1)  logL(x1þ x2)] where logL(x1) (logL(x1þx2)) is the log likelihood from a logistic regression with case-control status as the
dependent variable and x1 (x1 and x2) as independent explanatory variable.
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With increasing sample sizes, the odds ratio is expected to
increase further.37
We also quantified the gain in prediction accuracy from
MTGBLUP in terms of sample size. Using recent results
on prediction accuracy of polygenic scores derived from
quantitative genetic theory,11,38 we inferred the sample
sizes required to achieve the accuracies observed by the
methods (Figure 2). We assumed prevalence of 1% for
schizophrenia, 1% for bipolar disorder, and 15% for
major depressive disorder. The proportion of cases in
the sample was based on the real structure of the discov-
ery data (59% for schizophrenia, 64% for bipolar disorder,
and 57% for major depressive disorder). The effective
number of SNPs was assumed to be 69,748 calculated
with a weighted SNP method.39 The observed accuracy
was within the theoretical expectation for schizophrenia
and bipolar disorder, but not for major depressive
disorder where the actual predictive power was lower.
Accuracy of risk prediction for individual traits benefited
from including the correlated disorders. The gain in
accuracy of MTGBLUP compared to STGBLUP was equiv-
alent to increasing the sample size for schizophrenia,
bipolar disorder, and major depressive disorder by
~4,660 (95% confidence interval: 3,110–6,270), ~5,560
(2,830–8,640), and ~10,940 (730–24,440) individuals,
respectively (Figure 2). Gains in accuracy were even
greater with the CNS annotation model (Table S6). The
95% confidence interval was obtained according to the
sampling error of the difference between the prediction
accuracies (Appendix C).
In order to test how sensitive our results on prediction
are against population stratification, we re-estimated the
prediction accuracy (correlation), removing potential
outliers that were 56 SD, 2 SD, 1.75 SD, 1.5 SD, 1.25 SD,
or 1 SD away from the mean of the first and second prin-
cipal component in the validation dataset (Figure S6).
The accuracy of MTGBLUP and STGBLUP remained stable
in all three diseases for which independent datasets were
available. Restricting the samples to individuals whose
values of the first and second principal component lay
within one SD of the mean retained between 51% and
70% of the samples (Figure S6). This shows that the predic-
tion accuracy was not substantially affected by ancestry
outliers in the validation dataset.
We compared the performance of MTGBLUP with that
of bivariate GBLUP (a special case of MTGBLUP). The
accuracy of MTGBLUP was significantly higher than
bivariate GBLUP except for a major depressive disorder
risk prediction where the accuracy of MTGBLUP and that
of the bivariate model involving schizophrenia and
major depressive disorder was not significantly different
(Table S7 and S8).
Psychiatry lagsbehindotherfieldsofmedicine in termsof
diagnostic tests that could facilitate early diagnosis and
accurate classification of disorders. The considerable herita-
bility of psychiatric disorders implies that the genome
contains a large amount of information with potential
diagnostic utility. However, the highly polygenic nature
of psychiatric disorders makes it very hard to exploit this
information, mostly because the effect of each individual
locus contributing to disease risk can be estimated only
with error, and the size of the error depends on factors
such allele frequency, effect size, and (crucially) sample size.
The genetic correlation between several diseases implies
that a SNP contributing to risk of one disease will, on
average, also be informative of the risk of the correlated
diseases. Here, we have developed a multivariate method
that can combine data from an arbitrary number of genet-
ically correlated diseases, resulting in better estimates of
the disease-specific SNP effects and thus generating more
accurate predictors of individual risk. Our results demon-
strate a significant advantage of incorporating data from
Figure 1. Odds Ratios of Individuals Stratified into Deciles
Based on GBLUP Genetic Risk in Independent Samples, using
the Decile with the Lowest Risk as the Baseline
The vertical error bars denote 95% CI. We note that the estimates
for the different methods are highly correlated, and therefore the
vertical error bars cannot be used to infer significance of difference
between the methods (see Appendix C).
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multiple correlated diseases compared to single-trait ana-
lyses. Our estimates of pairwise genetic correlations ob-
tained in independent datasets reconfirm previous results
regarding the extent of genetic correlations between the
five psychiatric disorders.12 External validation demon-
strated that the predictive models generalize to other
populations, confirming that the correlations reflect
pleiotropy between the disorders rather than artifacts.
We used a multiple random effects model that fitted
two components, one due to annotated SNPs and the other
due to the rest of SNPs. The prediction accuracy signifi-
cantly increased when using an appropriate gene set. For
example, the gain in predictive accuracy in terms of sample
size equivalence increased from 4,660 to 5,080 for schizo-
phrenia, from 5,550 to 6,220 for bipolar disorder, and
from 10,940 to 11,550 for major depressive disorder
when using the CNS genes annotation12,26 (Table S6).
This demonstrates that the multiple random effects model
in MTGBLUP can be useful especially for psychiatric disor-
ders where prediction accuracy is hardly improved by
other advanced methods.4,5
Zhou and Stephens40 recently introduced a multivariate
linear mixed model algorithm that is particularly suited for
genome-wide association studies. Their method requires
that multiple traits are measured on the same individual
or that the level of missingness is sufficiently small so
that missing phenotypes can be imputed. However, this
algorithm is not useful when phenotypes are collected
from independent datasets as in the PGC data where
dependent variables are totally missing for the other four
traits as is typical of disease-ascertained cohorts. Moreover,
the efficiency of Zhou and Stephens’ algorithm sub-
stantially decreases when fitting multiple random effects
(e.g., the annotation model).
Korte et al.41 proposed a similar model to MTGREML
using ASReml42 that is as flexible as our method in that it
can handle partial overlapping or disjoint sets of pheno-
types. However, our algorithm is different from that used
in ASReml and ismuchmore efficient when using genomic
data20 (see Appendix A). Moreover, Korte et al. did not
explore their method with respect to improvements in
risk prediction.
Even though sensitivity and specificity of genetic diag-
nostics to predict an individual’s risk of psychiatric disor-
ders are generally low, genetic risk scores can still be a
valuable tool for research to stratify a heterogeneous pop-
ulation in groups with shared ‘‘genomic’’ characteristics.
It was suggested that psychiatric diagnoses encompass
several clinically similar phenotypes with distinct patho-
physiology and that stratification according to individual
heterogeneity is an important requirement for the
development of treatments targeted at specific disease
subtypes.17–19 Our proposed multivariate approach with
the annotation model is a flexible and powerful tool for
such stratification. TheMTGREML andMTGBLUP package
and documentation are publicly available online, which
we anticipate will be implemented into the GCTA pack-
age.22 Using a CPU running at 2.2 GHz, analyzing 58,128
samples with 5 disjoint sets of phenotypes (e.g., the PGC
data) takes ~7 hr per each iteration in MTGREML. Conver-
gence is usually achieved within 10 iterations. The virtual
memory required for such data is ~45 GB. Good starting
values (probably from single-trait GREML41) can reduce
the number of iterations to convergence and our software
has the option to provide starting values. The computa-
tional time increases cubically with sample size, e.g.,
analyzing sample size of 10,000 takes a few minutes per
each iteration. Our software provides a parallelization op-
tion that can reduce computational burden substantially;
Figure 2. Theoretical and Observed Prediction Accuracy of
STGBLUP and MTGBLUP Depending on Sample Size
Theoretical line of prediction accuracy increased with larger sam-
ple size (solid line), the observed accuracy achieved by STGBLUP
with the actual sample size (red dot), and the observed accuracy
achieved by MTGBLUP and inferred sample size (blue dot).
The increase from MTGBLUP equates to ~4,660 samples for
schizophrenia, ~5,550 samples for bipolar disorder, and ~10,940
for major depressive disorder. The vertical error bars denote
95% CI. We note that the estimates for the different methods
are highly correlated, and therefore the vertical error bars cannot
be used to infer significance of difference between the methods
(see Appendix C).
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for example, speed is increased by a factor of ten when
using 20 CPUs. The number of traits hardly affects running
time if phenotypes are non-overlapping.
Appendix A. Average of Hessian and Fisher
Information Matrix for the Multivariate Model
The log likelihood of the multivariate model is
ln L ¼ 1
2

ln jV j þ ln jX0V1X j þ y0Py
where ln is the natural log and j j the determinant of the
associated matrices. The projection matrix is defined as
P ¼ V1 V1XðX0V1XÞ1X0V1 with
X ¼
2
4X1 / 0« 1 «
0 / Xn
3
5; and y ¼
2
4y1«
yn
3
5:
The Newton-Raphson algorithm obtains the MTGREML
estimates with the following equation43
Qðkþ1Þ ¼ QðkÞ  HðkÞ1 vL
vQ
jQðkÞ (Equation A1)
where Q is a column vector of estimated variance compo-
nents, k is the iteration round, vL=vQ is a column vector of
the first derivatives of the log likelihood function with
respect to each variance component, and H is the Hessian
matrix, which consists of the second derivatives of the
log likelihood function with respect to the variance com-
ponents. In Fisher’s scoring method, the inverse of the
Hessian matrix in Equation A1 is replaced by its expected
value:43
Qðkþ1Þ ¼ QðkÞ þ FðkÞ1 vL
vQ
jQðkÞ: (Equation A2)
The derivation of the Hessian matrix and the Fisher
information matrix has been described in several
studies.43,44 The Hessian matrix for the multivariate
model is
H ¼ v
2L
vs2i vs
2
j
¼ 1
2
"
tr
 
vV
vs2i
P
vV
vs2j
P
!
 y0 vV
vs2i
P
vV
vs2j
PPy
#
(Equation A3)
where y, P, and V are defined in the section ‘‘Multivariate
Linear Mixed Model’’ in the main text. The Fisher informa-
tion (F) matrix is
F ¼ E
 
v2L
vs2i vs
2
j
!
¼ 1
2
"
tr
 
vV
vs2i
P
vV
vs2j
P
!#
: (Equation A4)
Gilmour et al.42 and Johnson and Thompson45 used the
average of the H and F that was estimated based on Hen-
derson’s mixed model equation (MME).46 The MME-based
average information algorithm is efficient particularly
when covariance structure fitted in the model is sparse.
Lee and van der Werf20 introduced the direct average
information algorithm where average information matrix
was derived directly from the V and Pmatrix. When using
non-zero elements of covariance structure, this direct
average information algorithm is much more efficient
than the MME-based average information algorithm. The
equation for the iterative AI algorithm is
Qðkþ1Þ ¼ QðkÞ þ AIðkÞ1 vL
vQ
jQðkÞ
where AI is the average information matrix and that for
multivariate model can be written as
AI ¼ 1
2
"
y0
vV
vs2i
P
vV
vs2j
PPy
#
:
The first derivative for each variance covariance compo-
nent i can be obtained as43,44
vL
vs2i
¼ 1
2
tr

P
vV
vs2i

þ 1
2
y0P
vV
vs2i
Py:
Appendix B. Reaction Norm Model to Test
Heterogeneity across Populations Classified
by the Ancestry Principal Component
Reaction normmodels have been used in ecology and evo-
lution to study genotype 3 environment interaction.35,36
Genotype 3 environment interaction (G 3 E) means that
different genotypes respond different to environmental
changes, i.e., norms of reaction. In the model, a random
intercept and a random slope, as covariance functions,
are estimated that can describe genetic and phenotypic
variation across different environments. The slope of the
reaction norm is often called phenotypic plasticity or envi-
ronmental sensitivity. The amount of variation in slope
in the population indicates the extent of G 3 E.35,36 Here,
we describe a reaction norm model to test heterogeneity
across populations. We group each sample set into four
populations by splitting them into the four quartiles of
the first ancestry principal component. Whereas typically
reaction norm models would compare samples with
different categories of environmental factors to each other,
we use the model to compare the samples in different
principal component quartiles to each other. We limit our
interpretation to heterogeneity across the groups and do
not speculate about potential causes like G 3 E or G 3 G
interaction. We apply the model to each disorder of the
PGC data. Incorporating population difference among
samples, the linear mixed model can be rewritten as
yij ¼ bij þ gij þ eij;
where yij is the observation for individual i in population
class j (j ¼ 1, ., P where P is the number of populations
classified by the ancestry principal component, in our
case four), bij is fixed effects, gij is genetic effects, and eij is
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residual effects. We applied a reaction norm model to fit
functions of the ancestry principal component as covari-
ables using Legendre polynomials.
yij ¼ bij þ
Xk1
m¼0
aimfm

pij
þ eij
pij is the average of the ancestry principal components in
the jth population class containing individual i, fm(pij)
is the mth Legendre polynomials evaluated for pij, aim is
the mth genetic random regression coefficients for the ith
individual, and k is the orders of fit. The genetic covariance
between individual i in population class j and i0 in popula-
tion class j0 is
cov

gij; gi0 j0
 ¼Xk1
m¼0
Xk1
l¼0
fm

pij

fl

pi0 j0

covðaim;ailÞ:
This can be written in a matrix form as
Vg ¼ FKF0 ;
where F is the matrix of Legendre polynomials evaluated
at given ancestry principal components and K is the
covariance coefficient matrix consisting of random regres-
sion coefficients, i.e.,
K ¼ covðaim;ailÞ ¼
2
4 varða0Þ / covða0;akÞ« 1 «
covðak;a0Þ / varðakÞ
3
5:
The optimal order of the polynomial was determined with
a likelihood ratio test by comparing the likelihood of
models with higher order to the null model with k ¼ 1.
Appendix C. Estimating the Sampling Error of the
Difference between Prediction Accuracies
It is assumed that there are three normalized variables
with the covariance structure as below, mimicking the
MTGBLUP, STGBLUP, and outcome variable.
We are interested in estimating the sampling error of the
difference between cor(m,y) and cor(s,y). The sampling
variance of the difference (s2d) can be expressed as
s2d ¼ s2corðm;yÞ þ s2corðs;yÞ  2,r,scorðm;yÞ,scorðs;yÞ; (Equation C1)
where s2corðm;yÞ is the sampling variance of cor(m,y), s
2
corðs;yÞ
is the sampling variance of cor(s,y), and r is the correlation
between cor(m,y) and cor(s,y). We show here that r is
approximately equal to cor(m,s).
With N records for each variable, correlations among
the variables can be written as
corðm; yÞ ¼ Eðm,yÞ ¼ 1
N
XN
i¼1
miyi
cor

s; y
 ¼ Es,y ¼ 1
N
XN
i¼1
siyi
cor

m; s
 ¼ Em,s ¼ 1
N
XN
i¼1
misi:
For T replicates, the expected value of the product of
cor(m,y) and cor(s,y) can be written as
E½Eðm,yÞ,Eðs,yÞ ¼ 1
T
XT
j
" 
1
N
XN
i¼1
miyi
! 
1
N
XN
i¼1
siyi
!#
j
¼ 1
T
XT
j
hm1y1
N
þ; :::;þmNyN
N
	s1y1
N
þ; :::;þsNyN
N
	i
j
:
If m and s are uncorrelated, this reduces to
E½EðmyÞ,EðsyÞ ¼ E½Eðm,yÞ,E½Eðs,yÞ
If m and s are correlated, there is an additional term,
E½Eðm,yÞEðs,yÞy
1
T
XT
j
" 
1
N2
XN
i¼1
misi
!#
jj
þ E½Eðm,yÞ,E½Eðs,yÞ ¼
1
T
XT
j


1
N
Eðm,sÞ

j
þ E½Eðm,yÞ,E½Eðs,yÞ ¼
1
N
E½Eðm,sÞ þ E½Eðm,yÞ,E½Eðs,yÞ
Therefore,
cov½Eðm,yÞ;Eðs,yÞ ¼ E½Eðm,yÞEðs,yÞ
 E½Eðm,yÞ,E½Eðs,yÞy1
N
E½Eðm,sÞ:
With var½Eðm,yÞyvar½Eðs,yÞy1=N, the correlation be-
tween cor(m,y) and cor(s,y) (r) can be approximated as
cor½Eðm,yÞ; Eðs,yÞyE½EðmsÞycorðm; sÞ:
This expression was checked and validated by simulations
(result not shown).
Here we have shown that Equation C1 can be used to
estimate the sampling variance (the square of the standard
error) of the difference in correlation between the
STGBLUP andMTGBLUP predictors (which are themselves
correlated with each other) and the outcome variable
(the adjusted phenotype). This allows us to estimate the
95% confidence interval of the increase in correlation
that MTGBLUP achieves over STGBLUP. Note that because
m s y
m 1 0.927 0.222
s 0.927 1 0.189
y 0.222 0.198 1
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the two predictors are correlated, this is a smaller confi-
dence interval than that of the correlation between
MTGBLUP and the outcome variable (which is shown in
Figures 1 and 2). By using the method described above,
we can transform the confidence interval from the correla-
tion scale to the sample size scale, to get estimates of the
effective increase in sample size achieved by MTGBLUP
(Table S6).
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